Search all trials

Find therapies in clinical trials near you – page 4

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Triple negative breast cancer

Not recruiting

Registered drugNo placebo

Study of Pembrolizumab, Carboplatin, and Paclitaxel for Patients with Stage I Triple-Negative Breast Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Triple negative breast cancer

Not recruiting

Registered drugNo placebo

Study on the Effectiveness and Safety of Datopotamab Deruxtecan Compared to Chemotherapy in Adults with Advanced Triple-negative Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Triple negative breast cancer+4

Not recruiting

Registered drugNo placebo

Study of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bt-001

Contact Research Centre

Triple negative breast cancer

Not recruiting

Registered drugNo placebo

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Avelumab

Contact Research Centre

Triple negative breast cancer

Not recruiting

Registered drugNo placebo

Study on Nivolumab with Paclitaxel and Carboplatin for Early Stage Triple Negative Breast Cancer Patients

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Nivolumab

Contact Research Centre

Triple negative breast cancer+9

Not recruiting

Registered drugNo placebo

Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Triple negative breast cancer+1

Not recruiting

Investigational

Study on Niraparib for Patients with HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Detected by ctDNA

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Niraparib Tosilate Monohydrate

Contact Research Centre

Triple negative breast cancer+13

Not recruiting

InvestigationalNo placebo

Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Fadraciclib

Contact Research Centre

Triple negative breast cancer

Not recruiting

Registered drugNo placebo

Study of Adagloxad Simolenin/OBI-821, Capecitabine, and Pembrolizumab for Patients with High-Risk, Early-Stage Triple Negative Breast Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Triple negative breast cancer

Not recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Durvalumab, Paclitaxel, and Drug Combinations for Patients with Metastatic Triple Negative Breast Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Capivasertib

Contact Research Centre

Triple negative breast cancer+7

Not recruiting

Registered drugNo placebo

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Triple negative breast cancer

Not recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Olaparib, Ceralasertib, and AZD1775 for Patients with Metastatic Triple Negative Breast Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Ceralasertib

Contact Research Centre

Find therapies in clinical trials near you – page 4

69 trials match your criteria

Triple negative breast cancer

Study of Pembrolizumab, Carboplatin, and Paclitaxel for Patients with Stage I Triple-Negative Breast Cancer

Triple negative breast cancer

Study on the Effectiveness and Safety of Datopotamab Deruxtecan Compared to Chemotherapy in Adults with Advanced Triple-negative Breast Cancer

Triple negative breast cancer+4

Study of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer

Triple negative breast cancer

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Triple negative breast cancer

Study on Nivolumab with Paclitaxel and Carboplatin for Early Stage Triple Negative Breast Cancer Patients

Triple negative breast cancer+9

Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy

Triple negative breast cancer+1

Study on Niraparib for Patients with HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Detected by ctDNA

Triple negative breast cancer+13

Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma

Triple negative breast cancer

Study of Adagloxad Simolenin/OBI-821, Capecitabine, and Pembrolizumab for Patients with High-Risk, Early-Stage Triple Negative Breast Cancer

Triple negative breast cancer

Study on the Safety and Effectiveness of Durvalumab, Paclitaxel, and Drug Combinations for Patients with Metastatic Triple Negative Breast Cancer

Triple negative breast cancer+7

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Triple negative breast cancer

Study on the Safety and Effectiveness of Olaparib, Ceralasertib, and AZD1775 for Patients with Metastatic Triple Negative Breast Cancer

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.